rituximab in pre-emptive therapy |
341 |
306 (89.7%) |
Administration of rituximab was often combined with other therapeutic approaches. |
rituximab in therapy of PTLD |
146 |
92 (63%) |
|
CTL in pre-emptive therapy |
135 |
127(94.1%) |
In most cases reported as a single therapy |
CTL in therapy of PTLD |
17 |
15 (88.2%) |
|
reduction of immunosuppressive therapy |
76 |
43 (56.6%) |
In most cases others therapies were also used |
Donor lymphocyte infusion |
39 |
16(41.0%) |
In most cases others therapies were also used |
Chemotherapy |
15 |
4(26.7%) |
In most cases others therapies were also used |
Cidofovir in combination with rituximab in pre-emptive therapy |
42 |
37(92.5%) |
In all cases others therapies were also used |
Antiviral agents in therapy of PTLD |
62 |
21(34.4%) |
|